Biocollection

PreclinicalBiologic

HHospices Civils de Lyon

Biocollection is one of 64 biologic programs targeting Aortic Stenosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic StenosisActive, not recruiting

Spinal Muscular AtrophyActive, not recruiting

Aortic StenosisPreclinical

Active, not recruiting

Spinal Muscular AtrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

53 competitors in Aortic Stenosis

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Approved

2 2

Lescol

Novartis

Approved

2 3

Zebeta

Teva

Approved

1 4

Simdax

Orion Corporation, Orion Pharma

Approved

1 5

Aldactone

Pfizer

Approved

1 6

Brilinta

AstraZeneca

Approved

1 7

Plavix

Sanofi

Approved

1 8

Bayer Aspirin

Savaysa

Niacor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Recruiting

Aortic Stenosis

NCT06713889

Q1 2029

N/ARecruiting

Spinal Muscular Atrophy

NCT06321965

Q2 2031

N/ARecruiting

STEMI

NCT05794022

Clinical

Trials by Indication[1]

STEMI1 trial

Cohort of STEMI Patients 2

Recruiting·HHospices Civils de Lyon·N/A·NCT05794022·300 enrolled

Aortic Stenosis1 trial

Identifying Biological Markers of Cardiovascular Events in Patients With Aortic Stenosis or TAVI

Recruiting·HHospices Civils de Lyon··NCT06713889·125 enrolled

Spinal Muscular Atrophy1 trial

Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy

Recruiting·HHospices Civils de Lyon·N/A·NCT06321965·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Biocollection. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biocollection compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biocollection. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: HHospices Civils de Lyon

Biocollection

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Q2 2031

Trials by Indication[1]

STEMI1 trial

Aortic Stenosis1 trial

Spinal Muscular Atrophy1 trial

References

Drug Info

Quick Facts

Related News